Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering

Donor lymphocyte infusion (DLI) is a key strategy for the treatment of AML relapse after allogeneic hematopoietic cell transplantation (allo-HCT) and has been used for either prophylactic, pre-emptive, or therapeutic purposes. However, the prognosis of these patients remains dismal even after DLI in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Yishan, Yang, Luxin, Yuan, Xiaolin, Huang, He, Luo, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829143/
https://www.ncbi.nlm.nih.gov/pubmed/35155192
http://dx.doi.org/10.3389/fonc.2021.790299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829143/
https://www.ncbi.nlm.nih.gov/pubmed/35155192
http://dx.doi.org/10.3389/fonc.2021.790299

Ejemplares similares